可降解聚乙交酯-丙交酯缓释微球用于甲状旁腺相关肽的持续释放

采用水包油包水(W1/O/W2)复乳溶剂挥发法制备了包载甲状旁腺激素相关肽(PTHrP)的聚乙交酯-丙交酯(PLGA)微球,通过核磁,红外,GPC,扫描电子显微镜等观察PLGA载药微球的结构,表明载药微球具有良好的球形结构,其平均粒径约为8μm.而体外模拟释放表明,此PLGA载药微球能实现PTHrP1-34长达25天的持续释放.并通过MTT法、碱性磷酸酶活性测定等检测负载PTHrP1-34的PLGA微球缓释系统对小鼠成骨细胞MC3T3-E1增殖及分化的影响,结果表明PTHrP1-34浓度为1×10-9mol/L时对MC3T3-E1增殖促进效应最大,且随着药物作用时间的延长,缓释系统促进细胞增殖、分化的作用越明显.     

聚羟基丁酯酯缓释微球的制备及性能

用溶剂蒸发法制备了以新型生物可降解材料聚羟基丁酸酯为载体、以安定为模药的缓释微球,讨论了药物与载体之比对药物含量与包封率的影响,以及制备微球条件对药物释放性能的影响;微球平均粒径为３０～４０μｍ,粒径分布在１～１．５之间,最大载药量为１９．５１％;最高包封率为６７．１１％;体外累积释放曲线呈“两相”释放特征并拌随初始的“突释效应”。扫描电镜观察微球表面呈皱缩表观形态结构,微球内部横断面具有孔道与孔     

聚羟基丁酸酯缓释微球的制备与性能

用溶剂蒸发法制备了以新型生物可降解材料聚羟基丁酸酯为载体、以安定为模药的缓释微球,讨论了药物与载体之比对药物含量与包封率的影响,以及制备微球条件对药物释放性能的影响;微球平均粒径为30～40 μm,粒径分布在 1～1.5之间,最大载药量为19.51%;最高包封率为67.11%;体外累积释放曲线呈"两相"释放特征并拌随初始的"突释效应".扫描电镜观察微球表面呈皱缩表观形态结构,微球内部横断面具有孔道与孔洞,在4℃与室温(20～25 ℃)条件下密封,避光环境下性质稳定.     

阿司匹林-蒙脱土-壳聚糖缓释微球的制备及其体外释放性能

利用溶液法预先制备壳聚糖(Cs)-蒙脱土(MMT)复合材料(Cs-MMT),以Cs-MMT、Cs为原料,采用反相悬浮聚合法制得一种新型药物缓释体系阿司匹林-蒙脱土-壳聚糖载药微球(Asp-MMT-Cs)。采用FT-IR、SEM表征了Cs-MMT和Asp-MMT-Cs载药微球的结构及形态;设计正交实验优化了Asp-MMT-Cs载药微球的制备工艺;通过体外释放实验探讨了载药微球在不同模拟释放液中的释药规律。结果表明:所得微球球形度好,粒径分布较均匀;最优工艺制得的载药微球平均粒径为81.20μm,载药量为9.61%,包封率为76.78%。该缓释体系具有pH敏感性,更倾向于在pH较高的磷酸盐缓冲溶液中释放。     

循环应力下PLGA多孔支架对地塞米松的控制释放

摘要 采用喷雾干燥法制备包载地塞米松(Dex)的聚L-丙交酯-b-聚乙二醇(PLLA-PEG)微球, 以热致相分离/粒子洗去法制备聚乙交酯-co-丙交酯(PLGA)多孔支架, 通过复合溶结法将载药微球固定于PLGA多孔支架中, 制得载药微球-支架(记为MS-S). 另外, 在支架制备过程中将Dex直接加入PLGA溶液中, 制得对比的直接载药支架(记为D-S). 以扫描电镜观察微球和支架的微观形貌, 在循环压应力与水浴摇床两种环境下分别对上述两种载药支架进行控制释放Dex的实验, 用紫外-可见光分光光度计测定Dex的累积释放量. 结果表明, Dex及微球的载入对PLGA支架的整体形貌影响较小; 循环压应力显著提高了Dex从载药支架中的释放速率, 与D-S相比, MS-S延缓了药物的释放. 研究模拟体内循环压应力下支架控制释放药物规律对于实现理想的临床效果具有重要意义.     

聚[碳酸(亚丁酯-co-ε-己内酯)酯]的制备及其载药微球性能的研究

采用阴离子配位聚合方法, 合成了二氧化碳、1,2-环氧丁烷与ε-己内酯的三元共聚物: 聚[碳酸(亚丁酯-co-ε-己内酯)酯](PBCL). 并采用复相乳液(W/O/W)溶剂挥发法制备了包裹抗菌药物甲磺酸帕珠沙星的可降解微球. 对聚合物进行了FTIR, ¹H NMR, ¹³C NMR, DSC, TGA和WAXD等表征, 以及降解性能和载药微球特性的研究. 结果表明, PBCL热稳定性及降解性能优于聚碳酸亚丁酯(PBC). 所得PBCL微球球形规整、表面光滑. 大部分微球粒径在0.5～1 μm的范围内, 载药量和包封率分别达到38.21%和87.9%. 微球的体外释药性能研究在pH 7.4的磷酸缓冲溶液中进行, 释放21 d后, PBCL微球的累积释药量为84.74%, PBC微球的释药量仅为17.29%. 药物的体外释放行为符合Higuchi方程. PBCL载药微球具有长效缓释作用.     

聚(L-谷氨酸)微球的制备及其口服药物控释研究

通过正己胺引发γ-苯甲基-L-谷氨酸酯-N-内羧酸酐(BLG-NCA)开环聚合制备聚(γ-苯甲基-L-谷氨酸酯)(PBLG), 并进一步脱掉苯甲基保护得到聚(L-谷氨酸)(PLG). 以利福平为模型药物, 通过油包油(O/O)无水乳液法制备了PLG载药微球. 扫描电子显微镜检测表明该载药微球具有良好的球形形貌且粒径分布较均一, 粒径大小约为9.0 μm. 体外释放实验表明该载药微球对利福平的释放具有明显的pH敏感性, 在模拟胃液中较少释放利福平, 而在模拟肠液中较快并大量释放利福平, 符合口服药物载体释放性能的要求, 可用于口服药物的定位肠溶性载体. 此外, 噻唑蓝实验表明该微球具有良好的生物相容性.     

以PHBV-PLGA为载体的硫酸庆大霉素缓释微球

以生物可降解聚羟基丁酸酯和羟基戊酸酯的共聚物(PHBV)、乙交酯和丙交酯的无规共聚物(PLGA)两种高分子作为壁材,采用复乳溶剂挥发法,制备了包裹硫酸庆大霉素(GS)的载药微球。在扫描电镜下观察到所得微球表面呈多孔状,为球形或椭圆形,粒径在20~80μm。分析结果表明,包封率在60%以上,在体外16~20 d内药物全部释放,90 d微球体外降解50%左右。     

可生物降解固体脂质纳米粒的制备、表征及药物的体外释放

以可生物降解材料硬脂酸为载体, 以葛根总黄酮为模型药物, 采用乳化蒸发-低温固化法制备固体脂质纳米粒. 采用透射电镜研究载药纳米粒形态, 激光粒度分析仪测定其粒径, X射线衍射仪进行物相鉴别, 并对纳米粒的包封率及体外释药特性等进行了研究. 分析结果表明, 所制备硬脂酸固态脂质纳米粒为类球实体, 粒径分布比较均匀, 平均粒径为(263.82±3.6) nm, 包封率为(67.53±0.12)%. X射线衍射分析证明药物以分子或细小粒子分散于脂质骨架中. 体外释药研究结果表明, 纳米粒体外释药先快后慢, 12 h累积释药50%, 包封于降解材料骨架内的药物通过骨架溶蚀缓慢释放. 药物的体外释放符合Higuchi方程.     

载万古霉素PLGA-PEG-PLGA温度敏感水凝胶的体外抗菌性能

利用聚乙二醇（PEG 1500）引发乙交酯和D,L-丙交酯开环共聚合制备聚丙交酯乙交酯（PLGA）三嵌段共聚物（PLGA-PEG-PLGA）温敏水凝胶材料,并通过核磁共振氢谱（¹H NMR）确定产物的结构及组成.应用倒置小瓶法测量得到不同浓度下PLGA-PEG-PLGA水凝胶的溶胶-凝胶相变温度为27~32℃.此外,体外降解实验及细胞毒性实验结果表明,质量分数为25%的水凝胶有满意的降解速度及良好的生物相容性.同时,利用紫外-可见光谱分析了载万古霉素水凝胶的体外药物释放行为,结果表明,万古霉素可以持续释放12 d.抗菌实验结果表明,载万古霉素水凝胶具有良好的抗菌效果.表明PLGA-PEG-PLGA三嵌段温敏水凝胶是一种较理想的万古霉素缓释载体,具有良好的临床应用前景.     

生物可降解5-氟尿嘧啶载药微球的制备及性能研究

5-氟尿嘧啶(5-Fu)为水溶性嘧啶类抗代谢药,是治疗实体肿瘤的首选药物．但5-Fu毒性很大,血浆中停留半衰期t1／2仅为10～20min．为了减少氟尿嘧啶的毒副作用并提高药物利用率,可以将其制成聚合物载药微球．聚酯类高分子是较为常用的生物降解型药物载体材料,其中聚乳酸(PLA)及其共聚物具有良好的生物相容性及生物可降解性,常被广泛应用于药物缓释材料,     

Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique

Monodisperse poly(lactide-co-glycolide) (PLGA) microspheres containing rifampicin (RFP), anti-tubercle drug, as hydrophobic model drug were prepared by solvent evaporation method with a membrane emulsification technique using Shirasu Porous Glass (SPG) membranes. Five kinds of rifampicin-loaded PLGA (RFP/PLGA) microspheres with different sizes were prepared by changing pore size of the membranes. Effect of polyethylene glycol (PEG) added to polyvinyl alcohol (PVA) solution (continuous phase) upon the monodispersity of microspheres was studied. PEG was used as a stabilizer for microspheres dispersing in PVA solution. The most suitable molecular weight of PEG as a stabilizer was 20,000. RFP/PLGA microspheres prepared with PEG20000 were apparently more uniform than those prepared without PEG. The yield of RFP/PLGA microspheres was 100%. The initial burst observed in the release of RFP from RFP/PLGA microspheres was suppressed by the addition of PEG.     

Preparation of PLGA microspheres with different porous morphologies

Poly(D,L-lactide-co-glycolide)(PLGA) microspheres were prepared by emulsion solvent evaporation method. The influences of inner aqueous phase, organic solvent, PLGA concentration on the morphology of microspheres were studied. The results showed that addition of porogen or surfactants to the inner aqueous phase, types of organic solvents and polymer concentration affected greatly the microsphere morphology. When dichloromethane was adopted as organic solvent, microspheres with porous structure were produced. When ethyl acetate served as organic solvent, two different morphologies were obtained. One was hollow microspheres with thin porous shell under a lower PLGA concentration, another was erythrocyte-like microspheres under a higher PLGA concentration. Three types of microspheres including porous, hollow core with thin porous shell(denoted by hollow in brief) and solid structures were finally selected for in vitro drug release tests. Bovine serum albumin(BSA) was chosen as model drug and encapsulated within the microspheres. The BSA encapsulation efficiency of porous, hollow and solid microspheres was respectively 90.4%, 79.8% and 0. And the ultimate accumulative release was respectively 74.5%, 58.9% and 0. The release rate of porous microspheres was much slower than that of hollow microspheres. The experiment results indicated that microspheres with different porous structures showed great potentials in controlling drug release behavior.     

分散聚合与水热处理相结合制备单分散聚苯乙烯微球的研究

将分散聚合与水热处理相结合,以聚乙烯醇为稳定剂,以乙醇和水为分散介质,三羟甲基丙烷三丙烯酸酯为交联剂,一步法成功制备得到不同粒径的单分散交联聚苯乙烯微球.以乙醇/水的比例为50/50的反应体系为基础,研究了聚乙烯醇类型和含量,有机相含量,引发剂浓度,以及水热釜填充量等对所制备的微球形貌的影响,发现聚乙烯醇类稳定剂的分子量的降低和含量的增多倾向于生成黏连的微球;在有交联剂的条件下,不含稳定剂的体系仍能够得到单分散的交联PS微球;有机相含量的增加会导致微球呈现多分散性;而体系中引发剂的含量和反应液在水热釜中的填充量对微球的形貌影响不大.进一步针对水热法的特点分析探讨了一步法成功制备单分散的交联聚苯乙烯微球的原因及其机理.     

Study of types and mixture ratio of organic solvent used to dissolve polymers for preparation of drug-containing PLGA microspheres

The effects of the types and the ratios of various organic solvents used as a mixtures to dissolve poly (lactide-co-glycolide) (PLGA) by using a solvent evaporation method, a technique used to prepare polymer particles, were carefully studied in order to investigate their advantages in developing drug delivery system (DDS) formulations for the prepared microspheres. The particle size and drug loading efficiency of drug-containing PLGA microspheres were found to be dependent on the types of solvent used due to the interfacial tension between the organic solvent and water phase. The drug loading efficiency of monodisperse microspheres prepared by using a membrane emulsification technique employing organic solvents and high interfacial tension for dissolving the PLGA was increased in a controlled manner. The organic solvents with high interfacial tension in the water phase used for the preparation of polymer particles by means of the solvent evaporation method were found to be suitable in terms of improvement in the properties of DDS formulations.     

Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist

A sustained release poly(DL-lactide-co-glycolide) (PLGA) microsphere delivery system to treat prostate cancer for a luteinizing hormone-releasing hormone (LHRH) antagonists, LXT-101 was prepared and evaluated in the paper. LXT-101 microspheres were prepared from PLGA by three methods: (1) double-emulsion solvent extraction/evaporation technique, (2) single-emulsion solvent extraction/evaporation technique, and (3) S/O/O (solid-in-oil-in-oil) method. The microspheres were investigated on drug loading, particle size, surface morphology and in vitro release profiles. An accelerated release approach was also established in order to expedite the evaluation periods. The in vivo evaluation of the microspheres was made by monitoring testosterone levels after subcutaneous administration to rats. The LXT-101 PLGA microspheres showed smooth and round surfaces according to a scanning electron microscopic investigation, and average particle size of ca. 30 mum according to laser diffractometry. The drug encapsulation efficiency of microspheres was influenced by LA/GA ratio of PLGA, salt concentrations, solvent mixture and preparation methods. Moreover, LA/GA ratio of PLGA, different preparation methods and different peptide stabilizers affected in vitro release of drugs. In vivo study, the testosterone levels were suppressed to castration up to 42 d as for the 7.5 mg/kg dose. And in vivo performance of LXT-101 microspheres was dose-dependent. The weights of rat sexual organs decreased and histopathological appearance of testes had little changes after 4-month microspheres therapy. This also testified that LXT-101 sustained release microspheres could exert the efficacy to suppress the testosterone level to castration with little toxicity. In conclusion, the PLGA microspheres could be a well sustained release system for LXT-101.     

PLGA/TiO2纳米药物缓释载体的研究

首先利用硅烷偶联剂(KH550)对纳米二氧化钛表面进行预处理,得到氨基改性的二氧化钛,然后与带有高活性端基的丙交酯-乙交酯共聚物(PLGA)反应,制备纳米药物缓释载体PLGA/TiO2有机-无机杂化材料.通过核磁(1H-NMR)、傅里叶变换红外光谱仪(FTIR)、热重分析(TGA)、扫描电子显微镜(SEM)、透射电子显...     

Development of biodegradable co-poly( -lactic/glycolic acid) microspheres for the controlled release of 5-FU by the spray drying method

The water-soluble anti-cancer drug, 5-fluorouracil (5-fluoro-2,4-pyrimidinedione) (5-FU) is encapsulated into biodegradable co-poly ( -lactic/glycolic acid) (PLGA) using the spray drying method for the development of long-lasting controlled release systems. In this study, the effects of both polymeric composition and technological parameters on release profiles of 5-FU were investigated. The degradation of various microspheres was also investigated. The mixture of dichloromethane/chloroform/methanol (1:1:2 v/v) instead of dichloromethane/chloroform (1:1 v/v) resulted in the modification of morphology, while the physical structure of the microsphere varied from a porous PLGA microsphere to a dense PLGA microsphere. The results show that the average diameter was 2 μm and the anti-cancer drug loading of microspheres approached approximately 8% (w/w). In addition, the lactide/glycolide ratio of the polymer is an important parameter for controlling the release profile of the entrapped anticancer drug. Our results indicate that the mixture solvent using the spray drying method was more efficient than emulsification solvent diffusion.     

聚二乙烯基苯微球的合成及其表征研究

采用分散聚合方法制备了聚二乙烯基苯微球 ,研究了引发剂、稳定剂、单体 溶剂比例和溶剂种类对微球粒径及其分布的影响 ,在适当的条件下可以得到平均粒径较大、粒径分布较窄的微球 .用红外光谱法研究了聚合物微球内稳定剂、悬挂双键以及对位和间位二乙烯基苯含量随聚合过程的进行发生的变化 .测得的微球TG曲线表明 ,聚合物微球具有良好的热稳定性 .     

Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres

Exenatide (synthetic exendin-4), a 39-amino acid peptide, was encapsulated in poly(DL-lactic-co-glycolic acid) (PLGA) microspheres as a sustained release delivery system for the therapy of type 2 diabetes mellitus. The microspheres were prepared by a double-emulsion solvent evaporation method and the particle size, surface morphology, drug encapsulation efficiency, in vitro release profiles and in vivo hypoglycemic activity were evaluated. The results indicated that the morphology of the exenatide PLGA microspheres presented as a spherical shape with smooth surface, and the particle sizes distributed from 5.8 to 13.6 μm. The drug encapsulation efficiency tested by micro-bicinchoninic acid (BCA) assay was influenced by certain parameters such as inner and outer aqueous phase volume, PLGA concentration in oil phase, polyvinyl alcohol (PVA) concentrations in outer aqueous phase. Moreover, in vitro release behaviors were also affected by some parameters such as polymer type, PLGA molecular, internal aqueous phase volume, PLGA concentration. The pharmacodynamics in streptozotocin (STZ)-induced diabetic mice suggested that, exenatide microspheres have a significant hypoglycemic activity within one month, and its controlling of plasma glucose was similar to that of exenatide solution injected twice daily with identical exenatide amount. In conclusion, this microsphere could be a well sustained delivery system for exenatide to treat type 2 diabetes mellitus.